Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance

References

• Hopsu-Havu VK, Glenner GG. A new dipeptide naphthylamidase hydrolyzing glycyl–prolyl-b-naphthylamide. Histochemie. 1966;201:197–201.
   Google Scholar
• Heymann E, Mentlein R. Liver dipeptidyl aminopeptidase IV hydrolyzes substance P. FEBS Lett. 1978;91(2):360–364. doi:10.1016/0014-5793(78)81210-1
   Web of Science ®Google Scholar
• Nicotera R, Casarella A, Longhitano E, et al. Antiproteinuric effect of DPP-IV inhibitors in diabetic and non-diabetic kidney diseases. Pharmacol Res. 2020;159:105019. doi:10.1016/j.phrs.2020.105019
   Web of Science ®Google Scholar
• Anderluh M, Kocic G, Tomovic K, Kocic H, Smelcerovic A. DPP-4 inhibition: a novel therapeutic approach to the treatment of pulmonary hypertension? Pharmacol Ther. 2019;201:1–7. doi:10.1016/j.pharmthera.2019.05.007
   PubMed Web of Science ®Google Scholar
• Yu DMT, Yao T, Chowdhury S, et al. The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J. 2010;277:1126–1144. doi:10.1111/j.1742-4658.2009.07526.x
   PubMed Web of Science ®Google Scholar
• Holst JJ. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia. 2006;49:253–260. doi:10.1007/s00125-005-0107-1
   PubMed Web of Science ®Google Scholar
• Iwanaga T, Nio-Kobayashi J. Cellular expression of CD26/dipeptidyl peptidase IV. Biomed Res. 2021;42(6):229–237. doi:10.2220/BIOMEDRES.42.229
   Web of Science ®Google Scholar
• Vanhoof G, Goossens F, Meester D, Hendriks D, Scharpé S. Proline motifs in peptides and their biological processing. FEBS J. 1995;9:736–744.
   Google Scholar
• Singh AK, Yadav D, Sharma N, Jin JO. Dipeptidyl peptidase (Dpp)‐iv inhibitors with antioxidant potential isolated from natural sources: a novel approach for the management of diabetes. Pharmaceuticals. 2021;14(6):586. doi:10.3390/ph14060586
   Web of Science ®Google Scholar
• Gupta S, Sen U. More than just an enzyme: dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling. Methods Mol Biol. 2019;176(5):139–148. doi:10.1016/j.phrs.2019.104391.More
   Google Scholar
• Koh JA, Ong JH, Manan FA, Ee KY, Wong FC, Chai TT. Discovery of bifunctional anti-dpp-iv and anti-ace peptides from housefly larval proteins after in silico gastrointestinal digestion. Biointerface Res Appl Chem. 2022;12(4):4929–4944. doi:10.33263/BRIAC124.49294944
   Web of Science ®Google Scholar
• Heike M, Mobius U, Knuth A, Meuer S, Zum KM, Medizinische BI. Tissue distribution of the T cell activation antigen Tal. Serological, immunohistochemical and biochemical investigations. Clin Exp Immunol. 1988;1640:431–434.
   Google Scholar
• Mentzel S, Dijkman HB, Van Son JP, Koene RA, Assmann KJ. Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice. Journal Histochem Cytochem. 1996;44(5):445–461. doi:10.1177/44.5.8627002
   PubMed Web of Science ®Google Scholar
• Deacon CF. Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes. Front Endocrinol. 2019;10:1–14. doi:10.3389/fendo.2019.00080
   Web of Science ®Google Scholar
• Röhrborn D, Wronkowitz N, Eckel J. DPP4 in diabetes. Front Immunol. 2015;6:1–20. doi:10.3389/fimmu.2015.00386
   Web of Science ®Google Scholar
• Itou M, Kawaguchi T, Taniguchi E, Sata M. Dipeptidyl peptidase-4: a key player in chronic liver disease. World J Gastroenterol. 2013;19(15):2298–2306. doi:10.3748/wjg.v19.i15.2298
   PubMed Web of Science ®Google Scholar
• Avogaro A, Kreutzenberg S, Fadini G. Dipeptidyl-peptidase 4 inhibition: linking metabolic control to cardiovascular protection. Curr Pharm Des. 2014;20(14):2387–2394. doi:10.2174/13816128113199990474
   Web of Science ®Google Scholar
• Casrouge A, Sauer AV, Barreira da Silva R, et al. Lymphocytes are a major source of circulating soluble dipeptidyl peptidase 4. Clin Exp Immunol. 2018;194(2):166–179. doi:10.1111/cei.13163
   PubMed Web of Science ®Google Scholar
• Jackman HL, Tan F, Schraufnagel D, et al. Plasma membrane-bound and lysosomal peptidases in human alveolar macrophages. Am J Respir Cell Mol Biol. 1995;13(2):196–204. doi:10.1165/ajrcmb.13.2.7626287
   Web of Science ®Google Scholar
• Shao S, Xu Q, Yu X, Pan R, Chen Y. Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions. Pharmacol Ther. 2020;209:107503. doi:10.1016/j.pharmthera.2020.107503
   PubMed Web of Science ®Google Scholar
• Trzaskalski NA, Fadzeyeva E, Mulvihill EE. Dipeptidyl peptidase-4 at the interface between inflammation and metabolism. Clin Med Insights Endocrinol Diabetes. 2020;13:1–10. doi:10.1177/1179551420912972
   Web of Science ®Google Scholar
• Lee SY, Wu ST, Liang YJ, et al. Soluble dipeptidyl peptidase-4 induces fibroblast activation through proteinase-activated receptor-2. Front Pharmacol. 2020;11:1–13. doi:10.3389/fphar.2020.552818
   Web of Science ®Google Scholar
• Engel M, Hoffmann T, Wagner L, et al. The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc Natl Acad Sci U S A. 2003;100(9):5063–5068. doi:10.1073/pnas.0230620100
   PubMed Web of Science ®Google Scholar
• Ohnuma K, Uchiyama M, Yamochi T, et al. Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1. J Biol Chem. 2007;282(13):10117–10131. doi:10.1074/jbc.M609157200
   Web of Science ®Google Scholar
• Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev. 2014;35(6):992–1019. doi:10.1210/er.2014-1035
   PubMed Web of Science ®Google Scholar
• Stulc T, Sedo A. Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects? Diabetes Res Clin Pract. 2010;88(2):125–131. doi:10.1016/j.diabres.2010.02.017
   PubMed Web of Science ®Google Scholar
• Zhong J, Kankanala S, Rajagopalan S. DPP4 inhibition: insights from the bench and recent clinical studies. Curr Opin Lipidol. 2017;176(5):139–148. doi:10.1097/MOL.0000000000000340.DPP4
   Google Scholar
• Shi S, Koya D, Kanasaki K. Dipeptidyl peptidase-4 and kidney fibrosis in diabetes. Fibrogenes Tissue Repair. 2016;9(1):1–10. doi:10.1186/s13069-016-0038-0
   Google Scholar
• Durinx C, Lambeir AM, Bosmans E, et al. Molecular characterization of dipeptidyl peptidase activity in serum soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-pro dipeptides. Eur J Biochem. 2000;267(17):5608–5613. doi:10.1046/j.1432-1327.2000.01634.x
   PubMedGoogle Scholar
• Cordero OJ, Salgado FJ, Nogueira M. On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother. 2009;58(11):1725–1749. doi:10.1007/s00262-009-0728-1
   Web of Science ®Google Scholar
• Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐ 1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993;214(3):829–835. doi:10.1111/j.1432-1033.1993.tb17986.x
   PubMedGoogle Scholar
• Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44(9):1126–1131. doi:10.2337/diab.44.9.1126
   PubMed Web of Science ®Google Scholar
• Brubaker PL, Drucker DJ. Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Recept Channels. 2002;8(3–4):179–188. doi:10.3109/10606820213687
   PubMedGoogle Scholar
• Ballantyne GH. Peptide YY(1-36) and peptide YY(3-36): part II. Changes after gastrointestinal surgery and bariatric surgery. Obes Surg. 2006;16(6):795–803. doi:10.1381/096089206777346619
   Web of Science ®Google Scholar
• Byrd JB, Touzin K, Sile S, et al. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor-associated angioedema. Hypertension. 2008;51(1):141–147. doi:10.1161/HYPERTENSIONAHA.107.096552
   Web of Science ®Google Scholar
• Mentlein R. Dipeptidyl-peptidase IV (CD26) -role in the inactivation of regulatory peptides. Regul Pept. 1999;85:9–24. doi:10.1016/S0167-0115(99)00089-0
   PubMed Web of Science ®Google Scholar
• Liu X, Murali SG, Holst JJ, Ney DM. Enteral nutrients potentiate the intestinotrophic action of glucagon-like peptide-2 in association with increased insulin-like growth factor-I responses in rats. Am J Physiol. 2008;295(6):1794–1802. doi:10.1152/ajpregu.90616.2008
   Web of Science ®Google Scholar
• Walsh NA, Yusta B, Dacambra MP, Anini Y, Drucker DJ, Brubaker PL. Glucagon-like peptide-2 receptor activation in the rat intestinal mucosa. Endocrinology. 2003;144(10):4385–4392. doi:10.1210/en.2003-0309
   PubMed Web of Science ®Google Scholar
• Mentlein R, Roos T. Proteases involved in the metabolism of angiotensin II, bradykinin, calcitonin gene-related peptide (CGRP), and neuropeptide Y by vascular smooth muscle cells. Peptides. 1996;17(4):709–720. doi:10.1016/0196-9781(96)00066-6
   Web of Science ®Google Scholar
• Ahrén B, Hughes TE. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice. Endocrinology. 2005;146(4):2055–2059. doi:10.1210/en.2004-1174
   PubMed Web of Science ®Google Scholar
• Lun SWM, Wong CK, Ko FWS, Hui DSC, Lam CWK. Increased expression of plasma and CD4+ T lymphocyte costimulatory molecule CD26 in adult patients with allergic asthma. J Clin Immunol. 2007;27(4):430–437. doi:10.1007/s10875-007-9093-z
   PubMed Web of Science ®Google Scholar
• Liu Z, Christensson M, Forslöw A, De Meester I, Sundqvist K-G. A CD26-controlled cell surface cascade for regulation of T cell motility and chemokine signals. J Immunol. 2009;183(6):3616–3624. doi:10.4049/jimmunol.0804336
   Web of Science ®Google Scholar
• Rai AK, Thakur CP, Kumar P, Mitra DK. Impaired expression of CD26 compromises T-cell recruitment in human visceral leishmaniasis. Eur J Immunol. 2012;42(10):2782–2791. doi:10.1002/eji.201141912
   Web of Science ®Google Scholar
• Struyf S, Proost P, Schols D, et al. CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J Immunol. 1999;162:4903–4909.
   PubMed Web of Science ®Google Scholar
• Lambeir AM, Proost P, Durinx C, et al. Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase iv reveals a striking selectivity within the chemokine family. J Biol Chem. 2001;276(32):29839–29845. doi:10.1074/jbc.M103106200
   PubMed Web of Science ®Google Scholar
• Wong PTY, Wong CK, Tam LS, Li EK, Chen DP, Lam CWK. Decreased expression of T lymphocyte co-stimulatory molecule cd26 on invariant natural killer t cells in systemic lupus erythematosus. Immunol Invest. 2009;38(5):350–364. doi:10.1080/08820130902770003
   PubMed Web of Science ®Google Scholar
• Crane M, Oliver B, Matthews G, et al. Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy. J Infect Dis. 2009;199(7):974–981. doi:10.1086/597276
   PubMed Web of Science ®Google Scholar
• Faidley TD, Leiting B, Pryor KD, Lyons K, Hickey GJ, Thompson DR. Inhibition of dipeptidyl-peptidase IV does not increase circulating IGF-1 concentrations in growing pigs. Exp Biol Med. 2006;231:1373–1378. doi:10.1177/153537020623100811
   Web of Science ®Google Scholar
• Sakurada C, Sakurada S, Hayashi T, Katsuyama S, Tan-No K, Sakurada T. Degradation of endomorphin-2 at the supraspinal level in mice is initiated by dipeptidyl peptidase IV: an in vitro and in vivo study. Biochem Pharmacol. 2003;66(4):653–661. doi:10.1016/S0006-2952(03)00391-5
   Web of Science ®Google Scholar
• Király K, Szalay B, Szalai J, et al. Intrathecally injected Ile-Pro-Ile, an inhibitor of membrane ectoenzyme dipeptidyl peptidase IV, is antihyperalgesic in rats by switching the enzyme from hydrolase to synthase functional mode to generate endomorphin 2. Eur J Pharmacol. 2009;620(1–3):21–26. doi:10.1016/j.ejphar.2009.08.018
   Web of Science ®Google Scholar
• Guieu R, Fenouillet E, Devaux C, et al. CD26 modulates nociception in mice via its dipeptidyl-peptidase IV activity. Behav Brain Res. 2006;166(2):230–235. doi:10.1016/j.bbr.2005.08.003
   PubMed Web of Science ®Google Scholar
• Tian L, Gao J, Hao J, et al. Reversal of new-onset diabetes through modulating inflammation and stimulating β-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor. Endocrinology. 2010;151(7):3049–3060. doi:10.1210/en.2010-0068
   PubMed Web of Science ®Google Scholar
• Zhang XY, De Meester I, Lambeir AM, et al. Study of the enzymatic degradation of vasostatin I and II and their precursor chromogranin A by dipeptidyl peptidase IV using high-performance liquid chromatography/electrospray mass spectrometry. J Mass Spectrom. 1999;34(4):255–263. doi:10.1002/(SICI)1096-9888(199904)34:4<255::AID-JMS752>3.0.CO;2-7
   Web of Science ®Google Scholar
• Radbakhsh S, Atkin SL, Simental-Mendia LE, Sahebkar A. The role of incretins and incretin-based drugs in autoimmune diseases. Int Immunopharmacol. 2021;98:107845. doi:10.1016/j.intimp.2021.107845
   Web of Science ®Google Scholar
• Gallwitz B. Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes. Diabetes Metab Syndr Obes Targets Ther. 2013;6:1–9. doi:10.2147/dmso.s23166
   PubMedGoogle Scholar
• Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016;4(6):525–536. doi:10.1016/S2213-8587(15)00482-9
   PubMed Web of Science ®Google Scholar
• Andukuri R, Drincic A, Rendell M. Alogliptin: a new addition to the class of DPP-4 inhibitors. Diabetes Metab Syndr Obes Targets Ther. 2009;2:117–126. doi:10.2147/dmsott.s4312
   PubMedGoogle Scholar
• Holst JJ. The incretin system in healthy humans: the role of GIP and GLP-1. Metabolism. 2019;96:46–55. doi:10.1016/j.metabol.2019.04.014
   PubMed Web of Science ®Google Scholar
• Salvatore T, Nevola R, Pafundi PC, et al. Incretin hormones: the link between glycemic index and cardiometabolic diseases. Nutrients. 2019;11(8):1–12. doi:10.3390/nu11081878
   Web of Science ®Google Scholar
• Kishimoto M. Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes Metab Syndr Obes Targets Ther. 2013;6:187–195. doi:10.2147/DMSO.S35682
   PubMedGoogle Scholar
• Ahrén B. Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. Diabetes Metab Syndr Obes Targets Ther. 2010;3:31–41. doi:10.2147/dmso.s7327
   PubMedGoogle Scholar
• Rehfeld JF. The origin and understanding of the incretin concept. Front Endocrinol. 2018;9:1–7. doi:10.3389/fendo.2018.00387
   Web of Science ®Google Scholar
• Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60(4):470–512. doi:10.1124/pr.108.000604
   PubMed Web of Science ®Google Scholar
• Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature. 1983;302(5910):716–718. doi:10.1038/302716a0
   PubMed Web of Science ®Google Scholar
• Ørskov C, Holst JJ, Knuhtsen S, Baldissera FGA, Poulsen SS, Nielsen OV. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology. 1986;119(4):1467–1475. doi:10.1210/endo-119-4-1467
   PubMed Web of Science ®Google Scholar
• Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest. 1987;79(2):616–619. doi:10.1172/JCI112855
   PubMed Web of Science ®Google Scholar
• Holst JJ, Ørskov C, Vagn Nielsen O, Schwartz TW. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett. 1987;211(2):169–174. doi:10.1016/0014-5793(87)81430-8
   PubMed Web of Science ®Google Scholar
• Ørskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology. 1988;123(4):2009–2013. doi:10.1210/endo-123-4-2009
   PubMed Web of Science ®Google Scholar
• Hsu WH, Sue SP, Liang HL, et al. Dipeptidyl peptidase 4 inhibitors decrease the risk of hepatocellular carcinoma in patients with chronic hepatitis C infection and type 2 diabetes mellitus: a Nationwide Study in Taiwan. Front Public Heal. 2021;9:1–6. doi:10.3389/fpubh.2021.711723
   Web of Science ®Google Scholar
• Eggstein S, Kreisel W, Gerok W, Eggstein M. Dipeptidyl aminopeptidase IV in hospitalized patients and in galactosamine hepatitis of the rat: activity and lectin affinity chromatography in serum and hepatic plasma membranes. J Clin Chem Clin Biochem. 1989;27:547–554.
   Google Scholar
• Nilius R, Stuhec K, Dietrich R. Changes of dipeptidylpeptidase IV as a membrane marker of lymphocytes in acute and chronic liver diseases–biochemical and cytochemical investigations. Physiol Res. 1991;40:95–102.
   Web of Science ®Google Scholar
• Matsumoto Y, Bishop GA, McCaughan GW. Altered zonal expression of the CD26 antigen (dipeptidyl peptidase IV) in human cirrhotic liver. Hepatology. 1992;15(6):1048–1053. doi:10.1002/hep.1840150613
   Web of Science ®Google Scholar
• Baumeier C, Schlüter L, Saussenthaler S, et al. Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease. Mol Metab. 2017;6(10):1254–1263. doi:10.1016/j.molmet.2017.07.016
   PubMed Web of Science ®Google Scholar
• Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med. 2013;19(7):850–858. doi:10.1038/nm.3184
   Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958–965. doi:10.1016/S0140-6736(01)06102-5
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2013;347(13):1673–1680.
   Google Scholar
• Itou M, Kawaguchi T, Taniguchi E, et al. Altered expression of glucagon-like peptide-1 and dipeptidyl peptidase IV in patients with HCV-related glucose intolerance. J Gastroenterol Hepatol. 2008;23(2):244–251. doi:10.1111/j.1440-1746.2007.05183.x
   Web of Science ®Google Scholar
• Casrouge A, Decalf J, Ahloulay M, et al. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest. 2011;121(1):308–317. doi:10.1172/JCI40594
   Web of Science ®Google Scholar
• Charles ED, Dustin LB. Chemokine antagonism in chronic hepatitis C virus infection. J Clin Invest. 2011;121(1):25–27. doi:10.1172/JCI45610
   PubMed Web of Science ®Google Scholar
• Dimitropoulou D, Karakantza M, Tsamandas AC, Mouzaki A, Theodorou G, Gogos CA. T-lymphocyte subsets in peripheral blood and liver tissue of patients with chronic hepatitis B and C. In vivo. 2011;25(5):833–840.
   Web of Science ®Google Scholar
• Rahman W, Huang P, Belov L, et al. Analysis of human liver disease using a cluster of differentiation (CD) antibody microarray. Liver Int. 2012;32(10):1527–1534. doi:10.1111/j.1478-3231.2012.02854.x
   Web of Science ®Google Scholar
• Sakata M, Kawahara A, Kawaguchi T, et al. Decreased expression of insulin and increased expression of pancreatic transcription factor PDX-1 in islets in patients with liver cirrhosis: a comparative investigation using human autopsy specimens. J Gastroenterol. 2013;48(2):277–285. doi:10.1007/s00535-012-0633-9
   PubMed Web of Science ®Google Scholar
• Miyajima I, Kawaguchi T, Fukami A, et al. Chronic HCV infection was associated with severe insulin resistance and mild atherosclerosis: a population-based study in an HCV hyperendemic area. J Gastroenterol. 2013;48(1):93–100. doi:10.1007/s00535-012-0610-3
   Web of Science ®Google Scholar
• Eslam M, Kawaguchi T, Del Campo JA, Sata M, Abo-Elneen Khattab M, Romero-Gomez M. Use of HOMA-IR in hepatitis C. J Viral Hepat. 2011;18(10):675–684. doi:10.1111/j.1365-2893.2011.01474.x
   Web of Science ®Google Scholar
• Fukushima N, Kuromatsu R, Arinaga-Hino T, et al. Adipocytokine involvement in hepatocellular carcinoma after sustained response to interferon for chronic hepatitis C. Hepatol Res. 2010;40(9):911–922. doi:10.1111/j.1872-034X.2010.00699.x
   Web of Science ®Google Scholar
• Sumie S, Kawaguchi T, Komuta M, et al. Significance of glucose intolerance and SHIP2 expression in hepatocellular carcinoma patients with HCV infection. Oncol Rep. 2007;18(3):545–552. doi:10.3892/or.18.3.545
   Web of Science ®Google Scholar
• Kawaguchi T, Ide T, Taniguchi E, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol. 2007;102(3):570–576. doi:10.1111/j.1572-0241.2006.01038.x
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Nagao Y, Tanaka K, et al. Causal relationship between hepatitis C virus core and the development of type 2 diabetes mellitus in a hepatitis C virus hyperendemic area: a pilot study. Int J Mol Med. 2005;16(1):109–114. doi:10.3892/ijmm.16.1.109
   Web of Science ®Google Scholar
• Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol. 2004;165(5):1499–1508. doi:10.1016/S0002-9440(10)63408-6
   PubMed Web of Science ®Google Scholar
• Pazienza V, Clément S, Pugnale P, et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology. 2007;45(5):1164–1171. doi:10.1002/hep.21634
   Web of Science ®Google Scholar
• Nishina S, Hino K. CD26/DPP4 as a therapeutic target in nonalcoholic steatohepatitis associated hepatocellular carcinoma. Cancers. 2022;14(2):454. doi:10.3390/cancers14020454
   Web of Science ®Google Scholar
• Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004;126:840–848. doi:10.1053/j.gastro.2003.11.056
   PubMed Web of Science ®Google Scholar
• Stone SF, Lee S, Keane NM, Price P, French MA. Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients. J Infect Dis. 2002;186(10):1498–1502. doi:10.1086/344892
   PubMed Web of Science ®Google Scholar
• Andrieu T, Thibault V, Malet I, et al. Similar increased serum dipeptidyl peptidase IV activity in chronic hepatitis C and other viral infections. J Clin Virol. 2003;27(1):59–68. doi:10.1016/S1386-6532(02)00128-2
   Web of Science ®Google Scholar
• Maes M, Bonaccorso S. Lower activities of serum peptidases predict higher depressive and anxiety levels following interferon-alpha-based immunotherapy in patients with hepatitis C. Acta Psychiatr Scand. 2004;109(2):126–131. doi:10.1046/j.0001-690X.2003.00230.x
   Web of Science ®Google Scholar
• Yang SS, Fu LS, Sen CC, Yeh HZ, Chen GH, Kao JH. Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C. J Gastroenterol Hepatol. 2006;21(12):1789–1793. doi:10.1111/j.1440-1746.2006.04677.x
   Web of Science ®Google Scholar
• Arase Y, Suzuki F, Kobayashi M, et al. Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus. Hepatol Res. 2011;41(6):524–529. doi:10.1111/j.1872-034X.2011.00798.x
   Web of Science ®Google Scholar
• Kaku K, Kadowaki T, Terauchi Y, et al. Sitagliptin improves glycaemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance. Diabetes Obes Metab. 2015;17(11):1033–1041. doi:10.1111/dom.12507
   PubMed Web of Science ®Google Scholar
• Sumida Y, Yoneda M, Hyogo H, et al. A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol. 2011;46(2):257–268. doi:10.1007/s00535-010-0305-6
   PubMed Web of Science ®Google Scholar
• Sumida Y, Yoneda M, Hyogo H, et al. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol. 2012;12(1):2. doi:10.1186/1471-230X-12-2
   PubMed Web of Science ®Google Scholar
• Eguchi Y, Hyogo H, Ono M, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012;47(5):586–595. doi:10.1007/s00535-012-0533-z
   PubMed Web of Science ®Google Scholar
• Powell EE, Wong VWS, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212–2224. doi:10.1016/S0140-6736(20)32511-3
   PubMed Web of Science ®Google Scholar
• Miyazaki M, Kato M, Tanaka K, et al. Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism. Mol Med Rep. 2012;5(3):729–733. doi:10.3892/mmr.2011.707
   PubMed Web of Science ®Google Scholar
• Cui J, Philo L, Nguyen P, et al. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol. 2016;65(2):369–376. doi:10.1016/j.jhep.2016.04.021
   PubMed Web of Science ®Google Scholar
• Alam S, Kabir J, Mustafa G, Gupta U, Hasan S, Alam A. Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial. Hepatic Med Evid Res. 2018;10(1):23–31. doi:10.4103/1319-3767.173762
   Web of Science ®Google Scholar
• Maiztegui B, Borelli MI, Madrid VG, et al. Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats. Clin Sci. 2011;120(2):73–80. doi:10.1042/CS20100372
   Web of Science ®Google Scholar
• Sujishi T, Fukunishi S, Ii M, et al. Sitagliptin can inhibit the development of hepatic steatosis in high-fructose diet-fed ob/ob mice. J Clin Biochem Nutr. 2015;57(3):244–253. doi:10.3164/jcbn.15-84
   Web of Science ®Google Scholar
• Lackner C. Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist’s perspective. Expert Rev Gastroenterol Hepatol. 2011;5(2):223–231. doi:10.1586/egh.11.8
   PubMed Web of Science ®Google Scholar
• Caldwell S, Ikura Y, Dias D, et al. Hepatocellular ballooning in NASH. J Hepatol. 2010;53(4):719–723. doi:10.1016/j.jhep.2010.04.031
   Web of Science ®Google Scholar
• Yilmaz Y, Yonal O, Deyneli O, Celikel CA, Kalayci C, Duman DG. Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. Acta Gastroenterol Belg. 2012;75(2):240–244.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes e state-of-The-art. Mol Metab. 2021;46:101102. doi:10.1016/j.molmet.2020.101102
   PubMed Web of Science ®Google Scholar
• Sachinidis A, Nikolic D, Pantea A, et al. Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors. Metabolism. 2020;111:154343. doi:10.1016/j.metabol.2020.154343
   PubMed Web of Science ®Google Scholar
• Li J, Albajrami O, Zhuo M, Hawley CE, Paik JM. Decision algorithm for prescribing SGLT2 inhibitors and GLP-1 receptor agonists for diabetic kidney disease. Clin J Am Soc Nephrol. 2020;15(11):1678–1688. doi:10.2215/CJN.02690320
   PubMed Web of Science ®Google Scholar
• Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Targher G. Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials. Metabolites. 2021;11(2):73. doi:10.3390/metabo11020073
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2021. Diabetes Care. 2021;44:S111–S124. doi:10.2337/dc21-S009
   PubMed Web of Science ®Google Scholar
• Ding X, Saxena NK, Lin S, Gupta N, Anania FA. Exendin-4, a Glucagon-Like Protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Gerontology. 2006;43(1):173–181. doi:10.1002/hep.21006.Exendin-4
   Google Scholar
• Gupta NA, Mells J, Dunham RM, et al. Glucagon-like Peptide-1 Receptor (GLP-1R) is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology. 2010;51(5):1584–1592. doi:10.1163/9789087905132_002
   PubMed Web of Science ®Google Scholar
• Dhir G, Cusi K. Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option. J Investig Med. 2018;66(1):7–10. doi:10.1136/jim-2017-000554
   Web of Science ®Google Scholar
• Svegliati-Baroni G, Saccomanno S, Rychlicki C, et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int. 2011;31(9):1285–1297. doi:10.1111/j.1478-3231.2011.02462.x
   PubMed Web of Science ®Google Scholar
• Trevaskis JL, Griffin PS, Wittmer C, et al. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. Am J Physiol. 2012;302(8):762–772. doi:10.1152/ajpgi.00476.2011
   PubMed Web of Science ®Google Scholar
• Rakipovski G, Rolin B, Nøhr J, et al. The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE −/− and LDLr −/− mice by a mechanism that includes inflammatory pathways. JACC Basic to Transl Sci. 2018;3(6):844–857. doi:10.1016/j.jacbts.2018.09.004
   PubMedGoogle Scholar
• Wang X, Ke J, Zhu YJ, et al. Dipeptidyl peptidase-4 (DPP4) inhibitor sitagliptin alleviates liver inflammation of diabetic mice by acting as a ROS scavenger and inhibiting the NFκB pathway. Cell Death Discov. 2021;7(1):1–10. doi:10.1038/s41420-021-00625-7
   Web of Science ®Google Scholar
• Velija-Asimi Z, Izetbegovic S, Karamehic J, et al. The effects of dipeptidyl peptidase-4 inhibitors in treatment of obese patients with type 2 diabetes. Med Arh. 2013;67(5):365–367. doi:10.5455/medarh.2013.67.365-367
   Google Scholar
• Klöting N, Fasshauer M, Dietrich A, et al. Insulin-sensitive obesity. Am J Physiol. 2010;299(3):506–515. doi:10.1152/ajpendo.00586.2009
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi:10.1002/hep.28431
   PubMed Web of Science ®Google Scholar
• Rufinatscha K, Radlinger B, Dobner J, et al. Dipeptidyl peptidase-4 impairs insulin signaling and promotes lipid accumulation in hepatocytes. Biochem Biophys Res Commun. 2017;485(2):366–371. doi:10.1016/j.bbrc.2017.02.071
   Web of Science ®Google Scholar
• Lamers D, Famulla S, Wronkowitz N, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes. 2011;60(7):1917–1925. doi:10.2337/db10-1707
   PubMed Web of Science ®Google Scholar
• Hattori S, Nomoto K, Suzuki T, Hayashi S. Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Diabetol Metab Syndr. 2021;13(1):1–6. doi:10.1186/s13098-021-00644-5
   Web of Science ®Google Scholar
• Foley JE, Jordan J. Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vasc Health Risk Manag. 2010;6(1):541–548. doi:10.2147/vhrm.s10952
   Google Scholar
• Balaban YH, Korkusuz P, Simsek H, et al. Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann Hepatol. 2007;6(4):242–250. doi:10.1016/s1665-2681(19)31905-2
   PubMed Web of Science ®Google Scholar
• Barchetta I, Ceccarelli V, Cimini FA, et al. Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD/NASH in individuals with and without obesity and metabolic disease. J Endocrinol Invest. 2021;44(5):979–988. doi:10.1007/s40618-020-01392-5
   Web of Science ®Google Scholar
• Ben-Shlomo S, Zvibel I, Shnell M, et al. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol. 2011;54(6):1214–1223. doi:10.1016/j.jhep.2010.09.032
   PubMed Web of Science ®Google Scholar
• Firneisz G, Varga T, Lengyel G, et al. Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker. PLoS One. 2010;5(8):e12226. doi:10.1371/journal.pone.0012226
   PubMed Web of Science ®Google Scholar
• Lee M, Shin E, Bae J, et al. Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression. Sci Rep. 2020;10(1):1–13. doi:10.1038/s41598-020-75288-y
   PubMed Web of Science ®Google Scholar
• Shirakawa J, Fujii H, Ohnuma K, et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes. 2011;60(4):1246–1257. doi:10.2337/db10-1338
   PubMed Web of Science ®Google Scholar
• Itou M, Kawaguchi T, Taniguchi E, Oriishi T, Sata M. Dipeptidyl peptidase IV inhibitor improves insulin resistance and steatosis in a refractory nonalcoholic fatty liver disease patient: a case report. Case Rep Gastroenterol. 2012;6(2):538–544. doi:10.1159/000341510
   Google Scholar
• Reynard MP, Turner D, Navarrete CV. Allele frequencies of polymorphisms of the tumour necrosis factor-α, interleukin-10, interferon-γ and interleukin-2 genes in a North European Caucasoid group from the UK. Eur J Immunogenet. 2000;27(4):241–249. doi:10.1046/j.1365-2370.2000.00227.x
   Google Scholar
• Lee JH, Park HJ, Kim YA, et al. The phenotypic characteristic of liver-derived stem cells from adult human deceased donor liver. Transplant Proc. 2012;44(4):1110–1112. doi:10.1016/j.transproceed.2012.02.020
   Web of Science ®Google Scholar
• Shaheen MBH. Hematopoietic cytokines and growth factors. In: Cord Blood Biology, Transplantation, Banking, and Regulation. AABB Press; 2011:35–74.
   Google Scholar
• Christopherson KW, Hangoc G, Broxmeyer HE. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1α-mediated chemotaxis of human cord blood CD34 + progenitor cells. J Immunol. 2002;169(12):7000–7008. doi:10.4049/jimmunol.169.12.7000
   PubMed Web of Science ®Google Scholar
• Christopherson KW, Hangoc G, Mantel CR, Broxmeyer HE. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science (80-). 2004;305(5686):1000–1003. doi:10.1126/science.1097071
   PubMed Web of Science ®Google Scholar
• Kawai T, Choi U, Liu PC, Whiting-Theobald NL, Linton GF, Malech HL. Diprotin A infusion into nonobese diabetic/severe combined immunodeficiency mice markedly enhances engraftment of human mobilized CD34+ peripheral blood cells. Stem Cells Dev. 2007;16(3):361–370. doi:10.1089/scd.2007.9997
   PubMed Web of Science ®Google Scholar
• Wyss BK, Donnelly AFW, Zhou D, Sinn AL, Pollok KE, Goebel WS. Enhanced homing and engraftment of fresh but not ex vivo cultured murine marrow cells in submyeloablated hosts following CD26 inhibition by Diprotin A. Exp Hematol. 2009;37(7):814–823. doi:10.1016/j.exphem.2009.03.005
   Web of Science ®Google Scholar
• Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91(11):4612–4619. doi:10.1210/jc.2006-1009
   PubMed Web of Science ®Google Scholar
• Ou X, O’Leary HA, Broxmeyer HE. Implications of DPP4 modification of proteins that regulate stem/progenitor and more mature cell types. Blood. 2013;122(2):161–169. doi:10.1182/blood-2013-02-487470
   PubMed Web of Science ®Google Scholar
• Blanchet X, Langer M, Weber C, Koenen R, von Hundelshausen P. Touch of chemokines. Front Immunol. 2012;3:1–18. doi:10.3389/fimmu.2012.00175
   Web of Science ®Google Scholar
• Lambeir AM, Díaz Pereira JF, Chacón P, et al. A prediction of DDP IV/CD26 domain structure from a physico-chemical investigation of dipeptidyl peptidase IV (CD26) from human seminal plasma. Biochim Biophys Acta. 1997;1340(2):215–226. doi:10.1016/S0167-4838(97)00045-9
   Web of Science ®Google Scholar
• Broxmeyer HE, Hoggatt J, Leary HAO, et al. Dipeptidylpeptidase 4 negatively regulates colony- stimulating factor activity and stress hematopoiesis. Nat Med. 2012;18(12):1786–1796. doi:10.1038/nm.2991
   PubMed Web of Science ®Google Scholar
• Proost P, Struyf S, Schols D, et al. Truncation of macrophage-derived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem. 1999;274(7):3988–3993. doi:10.1074/jbc.274.7.3988
   PubMed Web of Science ®Google Scholar
• Ye J. Mechanisms of insulin resistance in obesity. Front med. 2013;7(1):14–24. doi:10.1007/s11684-013-0262-6
   PubMed Web of Science ®Google Scholar
• Utzschneider KM, Kahn SE. The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2006;91(12):4753–4761. doi:10.1210/jc.2006-0587
   PubMed Web of Science ®Google Scholar
• Zuk PA, Zhu M, Ashjian P, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2002;13:4279–4295. doi:10.1091/mbc.E02
   PubMed Web of Science ®Google Scholar
• Sciences M, Sugimura A, Seki T. Cloning, expression, and characterization of a cDNA encoding a novel human growth factor for primitive hematopoietic progenitor cells. Proc Natl Acad Sci USA. 1997;94:7577–7582. doi:10.1073/pnas.94.14.7577
   Web of Science ®Google Scholar
• Tarantino G, Citro V, Balsano C, Capone D. Could SCGF-beta levels be associated with inflammation markers and insulin resistance in male patients suffering from obesity-related NAFLD? Diagnostics. 2020;10(6):395. doi:10.3390/diagnostics10060395
   Web of Science ®Google Scholar
• Mavier P, Martin N, Couchie D, Préaux AM, Laperche Y, Zafrani ES. Expression of stromal cell-derived factor-1 and of its receptor CXCR4 in liver regeneration from oval cells in rat. Am J Pathol. 2004;165(6):1969–1977. doi:10.1016/S0002-9440(10)63248-8
   Web of Science ®Google Scholar
• Duarte N, Coelho I, Holovanchuk D, Inês Almeida J, Penha-Gonçalves C, Paula Macedo M. Dipeptidyl peptidase-4 is a pro-recovery mediator during acute hepatotoxic damage and mirrors severe shifts in Kupffer cells. Hepatol Commun. 2018;2(9):1080–1094. doi:10.1002/hep4.1225
   Web of Science ®Google Scholar
• Campbell TB, Broxmeyer HE. CD26 inhibition and hematopoiesis: a novel approach to enhance transplantation. Front Biosci. 2008;13:1795–1805. doi:10.2741/2800
   PubMed Web of Science ®Google Scholar
• Jungraithmayr W, De Meester I, Matheeussen V, Baerts L, Arni S, Weder W. CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation. Eur J Cardio-Thoracic Surg. 2012;41(5):1166–1173. doi:10.1093/ejcts/ezr180
   PubMed Web of Science ®Google Scholar
• Kawakita E, Yang F, Kumagai A, et al. Metformin mitigates DPP-4 inhibitor-induced breast cancer metastasis via suppression of mTOR signaling. Mol Cancer Res. 2021;19(1):61–73. doi:10.1158/1541-7786.MCR-20-0115
   PubMed Web of Science ®Google Scholar
• Wilson CH, Abbott CA. Expression profiling of dipeptidyl peptidase 8 and 9 in breast and ovarian carcinoma cell lines. Int J Oncol. 2012;41(3):919–932. doi:10.3892/ijo.2012.1522
   Web of Science ®Google Scholar
• Aoe K, Amatya VJ, Fujimoto N, et al. CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma. Clin Cancer Res. 2012;18(5):1447–1456. doi:10.1158/1078-0432.CCR-11-1990
   Web of Science ®Google Scholar
• Zhang T, Tong X, Zhang S, et al. The roles of dipeptidyl peptidase 4 (DPP4) and DPP4 inhibitors in different lung diseases: new evidence. Front Pharmacol. 2021;12:1–9. doi:10.3389/fphar.2021.731453
   Web of Science ®Google Scholar
• Starska K, Głowacka E, Kulig A, Lewy-Trenda I, Bryś M, Lewkowicz P. The role of tumor cells in the modification of T lymphocytes activity - The expression of the early CD69+, CD71+ and the late CD25+, CD26+, HLA/DR+ activation markers on TCD4+ and CD8+ cells in squamous cell laryngeal carcinoma. Part I. Folia Histochem Cytobiol. 2011;49(4):579–592. doi:10.5603/FHC.2011.0081
   Web of Science ®Google Scholar
• McCaughan GW, Siah CL, Abbott C, Wickson J, Ballesteros M, Bishop G. Dipeptidyl peptidase IV is down‐regulated in rat hepatoma cells at the mRNA level. J Gastroenterol Hepatol. 1993;8(2):142–145. doi:10.1111/j.1440-1746.1993.tb01505.x
   Web of Science ®Google Scholar
• Nishina S, Yamauchi A, Kawaguchi T, et al. Dipeptidyl peptidase 4 inhibitors reduce hepatocellular carcinoma by activating lymphocyte chemotaxis in mice. Cell Mol Gastroenterol Hepatol. 2019;7(1):115–134. doi:10.1016/j.jcmgh.2018.08.008
   PubMed Web of Science ®Google Scholar
• Higurashi T, Hosono K, Takahashi H, et al. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol. 2016;17(4):475–483. doi:10.1016/S1470-2045(15)00565-3
   PubMed Web of Science ®Google Scholar
• Kawakita E, Koya D, Kanasaki K. CD26/DPP-4: type 2 diabetes drug target with potential influence on cancer biology. Cancers. 2021;13:2191. doi:10.3390/cancers13092191
   Web of Science ®Google Scholar
• Ming Z, Jiayi C, Yanyan Y, Zuquan Z, Lai X, Ra DM. Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. Sci Rep. 2017;7:8273. doi:10.1038/s41598-017-07921-2
   Web of Science ®Google Scholar
• Penaforte-Saboia JG, Couri CEB, Albuquerque NV, et al. Emerging roles of dipeptidyl peptidase-4 inhibitors in delaying the progression of type 1 diabetes mellitus. Diabetes Metab Syndr Obes Targets Ther. 2021;14:565–573. doi:10.2147/DMSO.S294742
   Web of Science ®Google Scholar
• Kissow H, Hartmann B, Holst JJ, et al. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. Regul Pept. 2012;179(1–3):91–100. doi:10.1016/j.regpep.2012.08.016
   PubMedGoogle Scholar
• Stecca BA, Nardo B, Chieco P, Mazziotti A, Bolondi L, Cavallari A. Aberrant dipeptidyl peptidase IV (DPP IV/CD26) expression in human hepatocellular carcinoma. J Hepatol. 1997;27(2):337–345. doi:10.1016/S0168-8278(97)80180-8
   Web of Science ®Google Scholar
• Kawakubo M, Tanaka M, Ochi K, et al. Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis–associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects. Sci Rep. 2020;10(1):1–11. doi:10.1038/s41598-020-57935-6
   Web of Science ®Google Scholar
• Iwamoto Y, Tajima N, Kadowaki T, et al. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metabol. 2010;12:613–622. doi:10.1111/j.1463-1326.2010.01197.x
   PubMed Web of Science ®Google Scholar
• Desai S, Brinker A, Joslyn Swann IS. Sitagliptin-associated drug allergy: review of spontaneous adverse event reports. Arch Intern Med. 2010;170(13):1169–1171. doi:10.1001/archinternmed.2010.188
   Google Scholar
• Hamasaki H, Yanai H. The development of angioedema in a patient with type 2 diabetes due to a novel dipeptidyl peptidase-IV inhibitor, anagliptin. Int J Cardiol. 2013;168(3):e106. doi:10.1016/j.ijcard.2013.07.257
   Web of Science ®Google Scholar
• Gosmanov AR, Fontenot EC. Sitagliptin-associated angioedema. Diabetes Care. 2012;35:2012. doi:10.2337/dc12-0574
   Google Scholar
• White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Al E. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–1335. doi:10.1056/NEJMoa1305889
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Athyros VG, Elisaf MS. The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors. Expert Opin Drug Metab Toxicol. 2014;10(6):787–812. doi:10.1517/17425255.2014.907274
   PubMed Web of Science ®Google Scholar